Nordhealth AS (STU:6E5) Research & Development: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6E5 Nordhealth AS STU:6E5
72 GF Score
Price €2.14
GF Value €3.37
! 1 Warning Sign
View Full Analysis

What is Nordhealth AS Research & Development?

Nordhealth AS STU:6E5 +2.88% 72 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:6E5 with a GF Score™ of 72/100 and a GF Value™ of €3.37. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nordhealth AS's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Nordhealth AS  (STU:6E5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nordhealth AS Research & Development Related Terms

Nordhealth AS Research & Development Historical Data

* Premium members only.

The historical data trend for Nordhealth AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nordhealth AS Research & Development Chart

Nordhealth AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nordhealth AS Quarterly Data
Apr21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:6E5
72GF Score
Nordhealth AS STU:6E5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nordhealth AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Nordhealth AS (STU:6E5) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Nordhealth AS and its competitors.
Is Nordhealth AS's Research & Development too high?
Nordhealth AS's current Research & Development is €0.00 Mil. Overall, Nordhealth AS has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Nordhealth AS's Research & Development compare to VEEV and BTSG?
Nordhealth AS's Research & Development of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nordhealth AS and its competitors. Nordhealth AS's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nordhealth AS stock overvalued right now?
Nordhealth AS (STU:6E5) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €3.37, compared to a current price of €2.14 — trading 36.5% below its estimated fair value. The current Research & Development is €0.00 Mil. Nordhealth AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nordhealth AS (STU:6E5), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nordhealth AS (STU:6E5) Overvalued in 2026?

Based on GuruFocus' analysis, Nordhealth AS stock appears to be undervalued. The current stock price of €2.14 is trading 36.5% below its estimated GF Value™ of €3.37.

Key valuation signals for STU:6E5:

  • Research & Development: €0.00 Mil
  • GF Value™: €3.37 vs. price of €2.14 (36.5% below fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the STU:6E5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nordhealth AS Business Description

Other Exchanges NORDH:Norway
Address Hasleveien 28A, Oslo, NOR, 0571
Nordhealth AS is a cloud-based healthcare Software-as-a-Service business. Its flagship Practice Management Software (PMS), Provet for veterinary practices and Therapy Unified Platform for therapy practices, assist healthcare professionals to streamline operations and improve patient care. The majority of its revenue is generated through software subscriptions. The Group also offers additional services related to the implementation of the SaaS systems, including consultancy services, education, and data conversion. Its operating segments are: Veterinary, which generates the majority of revenue, Therapy, and Other. Geographically, Nordhealth derives maximum revenue from Norway, and the rest from Finland, the United Kingdom, Sweden, Denmark, the DACH region, and other countries.
72GF Score

Get the complete analysis for STU:6E5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.14
Price
€3.37
GF Value